While ongoing stress from COVID-19 has had an effect on many people's mental health, contracting the virus may have much more of an impact on the brain.
While ongoing stress from COVID-19 has had an affect on many people's mental health, contracting the virus may have much more of an impact on the brain.
Recent reports are showing that some people are reporting they are experiencing post-COVID-19 symptoms of cognitive changes affecting memory, way of thinking and more.
President of Western University of Health and Sciences, Daniel R. Wilson, MD, PhD, and former president of the American Neuropsychiatric Association, has been closely monitoring the impact COVID-19.
Wilson has noted the virus is "effecting the brain in a way that reduces memory or concentration (as) a classic neuropsychiatric issue."
With this particular issue being one of the many effects of COVID-19, there is still more research be done on the virus and its cognitive affects
"More research is conducted every day as we continue to learn about the long-term impact of COVID-19 on the human mind and body," Wilson says. "Recent reports showing a loss of cognitive ability could impact people's ability to maintain their quality of life, performance at their job, and more."
Should the disease start to take away cognitive ability, the next downstream effect on some people could be mild depression or apathy, he adds.
It's currently up to time itself to tell if the percentage of those who have shown a drop in cognitive function will regain cognitive ability or if things will continue to deteriorate.
Wilson says it will be important to further investigate the extent to which cognition is impacted in the weeks and months after the infection, and whether permanent damage to brain function results in some people, as researchers seek to better understand the long-term impact of COVID-19.
"No study can claim a clear conclusion, but it is imperative that people do everything they can to protect themselves from contracting and/or spreading the COVID-19 virus," Wilson adds.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More